Session » (1770–1779) Cytokines & Cell Trafficking Poster

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1770

Brepocitinib Inhibits Key Pathogenic Cytokine Signaling in Dermatomyositis Patients

10:30AM-12:30PM: Abstract Number: 1774

Citrullinated and Malondialdehyde-Acetaldehyde Co-Modified Fibrinogen Activates Macrophages and Induces Pro-Fibrotic shift in Coronary Endothelium Phenotype

10:30AM-12:30PM: Abstract Number: 1779

Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium

10:30AM-12:30PM: Abstract Number: 1772

Correlation between Soluble Checkpoint Molecules and Disease Activity in Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 1777

Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus

10:30AM-12:30PM: Abstract Number: 1771

Interferon- α, Anti-Interferon-Alpha Antibodies and Disease Activity in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1776

Preclinical Development of a Novel TL1A-Targeting Antibody with Extended Half-life and Low Immunogenicity Risk for the Treatment of Inflammatory Diseases

10:30AM-12:30PM: Abstract Number: 1773

Redefining disease activity assessment in IgG4-Related Disease: The role of classical and novel biomarkers

10:30AM-12:30PM: Abstract Number: 1775

Study Of Type -1 Interferon Gene Signature Markers In Muscle Biopsy Samples Of Patients With IIM

10:30AM-12:30PM: Abstract Number: 1778

Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].